Global Prostate Cancer Therapeutics Market, By Drug Class (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Sales, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2029
Market Analysis and Insights Global Prostate Cancer Therapeutics Market
Prostate cancer therapeutics market is expected to gain market growth in the forecast period of 2022-2029. Data Bridge Market Research analyses the market to account to grow at a CAGR of 8.2% in the above mentioned forecast period and is likely to reach the value USD 21.90 billion by 2029.
Prostate cancer is a kind of cancer in which abnormal cells in the prostate gland proliferate and expand uncontrollably. Prostate cancer is the sixth leading cause of death in males, and the eleventh leading cause of death from any disease. Radiation, chemotherapy, hormone therapy, surgery and biological therapy are all options for treating prostate cancer. Prostate cancer is treated and managed with a variety of diagnostic and therapeutic items, including prostatic adenocarcinoma, small cell carcinoma, benign prostatic hyperplasia, and others.
The rise in the number of cases of prostate cancer and cardiovascular disorders is the major driver resulting in the expansion of market’s growth. Another significant factor influencing the growth rate of prostate cancer therapeutics market is the rising healthcare expenditure. Furthermore, growing government funding and rising initiatives by public and private organisations to spread awareness about prostate cancer are the factors that will expand the prostate cancer therapeutics market. Other factors such as technical innovations linked with screening and diagnostic tests and changing lifestyle will positively impact the prostate cancer therapeutics market’s growth rate. Additionally, developments in genomics and proteomics and growing geriatric population will cushion the growth rate of prostate cancer therapeutics market. Emergence of strong pipeline drugs and presence of new prostate cancer treatments are the significant factors that will escalate the growth rate of prostate cancer therapeutics market.
Moreover, the rise in the research and development activities and innovative drugs will provide beneficial opportunities for the prostate cancer therapeutics market in the forecast period of 2022-2029. Also, high unmet needs and rise in the pharmaceutical expenditure by emerging markets will escalate the growth rate prostate cancer therapeutics market in future.
However, high cost associated with the treatment and less success rate in clinical trials for oncology drugs will impede the growth rate of prostate cancer therapeutics market. Additionally, adverse effects involved with prostate cancer therapeutics will hinder the prostate cancer therapeutics market growth. Less awareness and prolonged treatment durations will further challenge the market in the forecast period mentioned above.
This prostate cancer therapeutics market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the prostate cancer therapeutics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Prostate Cancer Therapeutics Market Scope and Market Size
The prostate cancer therapeutics market is segmented on the basis of drug class, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- Based on drug class, prostate cancer therapeutics market is segmented into hormonal therapy, chemotherapy, immunotherapy and targeted therapy. Hormonal therapy has been further sub-segmented into luteinizing hormone-releasing hormone (LHRH) antagonists, luteinizing hormone-releasing hormone (LHRH) agonists and anti-androgen. Luteinizing hormone-releasing hormone (LHRH) antagonists have been divided into zytiga and gonax. Luteinizing hormone-releasing hormone (LHRH) agonists have been divided into lupron, zoladex, eligard, decapeptyl, vantas and others. Anti-Androgen has been divided into xtandi and casodex. Chemotheraphy has been further sub-segmented into taxotere and jevtana. Immunotheraphy has been further sub-segmented as provenge. Targeted therapy has been further sub-segmented as xofigo.
- On the basis of end-users, the prostate cancer therapeutics market is segmented into clinic, hospital and others.
- Prostate cancer therapeutics market has also been segmented on the basis of distribution channel into hospital pharmacies, retail pharmacies, online sales and others.
Prostate Cancer Therapeutics Market Country Level Analysis
Prostate cancer therapeutics market is analyzed and market size information is provided by the country, drug class, end-users and distribution channel as referenced above.
The countries covered in the prostate cancer therapeutics market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.
North America dominates the prostate cancer therapeutics market due to the presence of major key players, high disposable income and well-developed healthcare infrastructure in this region. Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to the increasing patient pool, rising investment in the healthcare sector, and growing government support.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Prostate cancer therapeutics market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Global Prostate Cancer Therapeutics Market Share Analysis
Prostate cancer therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to prostate cancer therapeutics market research.
Some of the major players operating in the prostate cancer therapeutics market are Johnson & Johnson Private Limited, Astellas Pharma Inc., Ipsen Pharma, Sanofi, Bayer AG, AbbVie Inc., AstraZeneca, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Abbott, Takeda Pharmaceutical Company Limited., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Novartis AG, F. Hoffmann-La Roche Ltd., Myovant Sciences GmbH, Tolmar Pharmaceuticals, Inc., Ferring B.V., Dendreon Pharmaceuticals LLC., and Genentech, Inc., among others.
- In January 2021, U.S. Food and Drug Administration (FDA) have approved a new drug named Relugolix which is expected to modify the treatment for advanced prostate cancer. The medicine relugolix (Orgovyx) was found to be more successful at lowering testosterone levels in men with advanced prostate cancer in a substantial clinical trial.
- In June 2021, Novartis AG has announced that the U.S. Food and Drug Administration (FDA) have granted Breakthrough Therapy designation (BTD) to 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC). Breakthrough Therapy designation is given to drugs that are being studied for critical illnesses and show early clinical evidence of a significant improvement over current therapy.